
|Articles|March 31, 2023
Drug Digest Editorial Interview Series: Fundamental Constriction Points in Emerging Therapies, High-Titre Vector-Producing Cells: Part 3
Benjamin McLeod, Technical Lead, Virica Biotech, speaks about fundamental constriction points in emerging therapies, high-titre vector-producing cells.
Advertisement
Benjamin serves as Technical Lead with Virica Biotech, a yield-enhancing solution for viral vector and cell therapy production. He is trained in cell biology, biotechnology, and viral vector production. You can find him on LinkedIn, where he regularly posts industry insights and curates papers on process development in CGT.
Register for the full webcast:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
2
FDA Clears PharmaResearch IND for Nano-Based Cancer Drug PRD-101
3
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
4
High-Dose Nusinersen Slows Neurodegeneration in SMA Patients, Study Shows
5



